Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4495949 | 0.94 | MAPT (0.45) | ALDH1A1PKMMAPTPOLBHRH3 | |
| SCHEMBL1100727 | 0.86 | ALDH1A1 (0.48) | ALDH1A1PKMMAPTPOLBSMN1; SMN2 | |
| SCHEMBL5221209 | 0.83 | ALDH1A1 (0.70) | ALDH1A1PKMMAPTPOLBSMN1; SMN2 | |
| SCHEMBL11501758 | 0.81 | ALDH1A1 (0.57) | ALDH1A1PKMMAPTPOLBHRH3 | |
| SCHEMBL3657869 | 0.78 | ALDH1A1 (0.44) | ALDH1A1PKMMAPTPOLB | |
| SCHEMBL1098531 | 0.78 | ALDH1A1 (0.44) | ALDH1A1PKMMAPTPOLBHRH3 | |
| SCHEMBL1097082 | 0.78 | MAOB (0.33) | — | |
| SCHEMBL7137154 | 0.78 | ALDH1A1 (0.50) | ALDH1A1PKMMAPTPOLBSMN1; SMN2 | |
| SCHEMBL11701515 | 0.78 | — | — | |
| SCHEMBL2576487 | 0.78 | ALDH1A1 (0.50) | ALDH1A1PKMMAPTPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802591-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-01-11 | — | — | EP | claimed |
| US-20090233924-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | claimed |
| US-7501516-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-03-10 | — | — | US | claimed |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | claimed |
| EP-1381599-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-09-24 | — | — | EP | claimed |
| EP-1562955-B1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | claimed |
| US-20070213367-A1 | Substituted 3-cyanoquinolines as MEK inhibitors | ASTRAZENECA AB | 2007-09-13 | — | — | US | claimed |
| US-20070191346-A1 | 3-Cyano-quinoline derivatives | ASTRAZENECA AB | 2007-08-16 | — | — | US | claimed |
| US-7223756-B2 | Quinazoline compounds with therapeutic use | ASTRAZENECA AB (SE) | 2007-05-29 | — | — | US | claimed |
| US-7173136-B2 | 3-Cyano-quinoline derivatives | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | claimed |
| WO-2003045395-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | claimed |
| WO-2003045364-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | claimed |
| WO-2003045943-A1 | QUINAZOLINE COMPOUNDS WITH THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | claimed |
| EP-1313727-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | claimed |
| WO-2002030924-A9 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | claimed |
| WO-2003008409-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | claimed |
| WO-2002085895-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | claimed |
| WO-2002030924-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | claimed |
| WO-2002030926-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | claimed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213367-A1 | Substituted 3-cyanoquinolines as MEK inhibitors | NRAS, BRAF, MAPK1 | ALDH1A1 1951/4885PKM 714/4885MAPT 4555/4885 |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | ALDH1A1 2449/4885PKM 1880/4885MAPT 3649/4885 |
| US-20090233924-A1 | Quinazoline derivatives | AQP1, PGF, F12 | ALDH1A1 2094/4885PKM 1705/4885MAPT 3010/4885 |
| US-20070191346-A1 | 3-Cyano-quinoline derivatives | MKI67, CCNA1, CCNT1 | ALDH1A1 1113/4885PKM 2170/4885MAPT 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.